NCT00288561View on ClinicalTrials.gov

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2004

Study Completion Date

July 31, 2007

Conditions
Age-Related Macular Degeneration (ARMD)
Interventions
DRUG

ranibizumab

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00288561 - Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter